HighVista Strategies LLC Has $2.44 Million Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)

HighVista Strategies LLC decreased its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT) by 19.7% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 225,633 shares of the technology company’s stock after selling 55,460 shares during the period. HighVista Strategies LLC’s holdings in Cogent Biosciences were worth $2,437,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Values First Advisors Inc. acquired a new stake in Cogent Biosciences during the 3rd quarter valued at $32,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Cogent Biosciences by 38.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,959 shares of the technology company’s stock valued at $43,000 after buying an additional 1,104 shares in the last quarter. nVerses Capital LLC bought a new position in shares of Cogent Biosciences in the third quarter valued at about $76,000. Quest Partners LLC bought a new position in shares of Cogent Biosciences in the second quarter valued at about $89,000. Finally, SkyView Investment Advisors LLC lifted its position in Cogent Biosciences by 25.0% during the 2nd quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the technology company’s stock worth $105,000 after buying an additional 2,500 shares in the last quarter.

Cogent Biosciences Stock Down 0.4 %

Shares of COGT stock opened at $9.47 on Tuesday. The firm’s 50 day moving average price is $10.71 and its two-hundred day moving average price is $9.71. Cogent Biosciences, Inc. has a 52-week low of $3.67 and a 52-week high of $12.61.

Cogent Biosciences (NASDAQ:COGT) last posted its quarterly earnings results on Tuesday, November 12th. The technology company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). During the same period last year, the company posted ($0.64) earnings per share. As a group, sell-side analysts expect that Cogent Biosciences, Inc. will post -2.4 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Needham & Company LLC lowered their price objective on shares of Cogent Biosciences from $16.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. JPMorgan Chase & Co. raised their price target on shares of Cogent Biosciences from $19.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Robert W. Baird upped their price objective on Cogent Biosciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a report on Thursday, September 5th. Wedbush reiterated a “neutral” rating and issued a $11.00 price objective on shares of Cogent Biosciences in a research report on Tuesday, November 12th. Finally, HC Wainwright restated a “buy” rating and set a $17.00 target price on shares of Cogent Biosciences in a research report on Monday, November 4th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.83.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.